Skip to content

Study · Animal study (in vivo) · rhesus monkey · 2019

4 results

Peripherally administered KP-10 prevents development of insulin-induced hypoglycemic shock in diabetic rhesus monkeys.

Qureshi IZ, Fatima I

Physiology international1 Dec 2019

PMID31896266 (opens in a new tab)DOI10.1556/2060.106.2019.31 (opens in a new tab)PepBankPUB-31896266
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic and healthy rhesus monkeys, KP-10 given before insulin allowed blood glucose to rise to significantly higher levels at 180 min than insulin alone.

    In plain wordsIn rhesus monkeys, kisspeptin‑10 given before insulin kept blood sugar higher than insulin alone.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseBlood glucose at 180 min after insulin
    Study

    rhesus monkeyn = 6

    Streptozotocin-induced diabetic and healthy male monkeys given insulin
    Comparator
    Insulin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Intergroup comparisons demonstrated that treatment with KP-10 prior to insulin administration and kisspeptin-insulin premix treatment allowed blood glucose levels to rise to significantly higher levels (p < 0.001) by 180 min in diabetic and healthy animals compared to treatment with insulin alone.
    2 context sentences
    Summary · context
    Thirty-six adult male rhesus monkeys were used, six in each group.
    Summary · context
    Diabetes was induced with streptozotocin (45 mg/kg b.w.; single dose i.v.).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic and healthy rhesus monkeys, a premix of KP-10 and insulin allowed blood glucose to rise to significantly higher levels at 180 min than insulin alone.

    In plain wordsIn rhesus monkeys, a premix of kisspeptin‑10 and insulin kept blood sugar higher than insulin alone.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseBlood glucose at 180 min after insulin
    Study

    rhesus monkeyn = 6

    Streptozotocin-induced diabetic and healthy male monkeys given insulin
    Comparator
    Insulin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    50 μgAs given in this study (rhesus monkey).

    Source sentences

    Summary
    Intergroup comparisons demonstrated that treatment with KP-10 prior to insulin administration and kisspeptin-insulin premix treatment allowed blood glucose levels to rise to significantly higher levels (p < 0.001) by 180 min in diabetic and healthy animals compared to treatment with insulin alone.
    3 context sentences
    Summary · context
    Groups were as: saline control, insulin alone, pre-insulin (treated with KP-10, 30 min before insulin), post-insulin (treated with KP-10, 30 min after insulin), treated with premix dose of KP-10 (50 μg) and insulin, and the group treated with the kisspeptin antagonist P234 (50 μg).
    Summary · context
    Thirty-six adult male rhesus monkeys were used, six in each group.
    Summary · context
    Diabetes was induced with streptozotocin (45 mg/kg b.w.; single dose i.v.).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic and healthy rhesus monkeys, KP-10 given after insulin did not prevent the glucose fall; glucose at 180 min was significantly lower than with insulin alone.

    In plain wordsIn rhesus monkeys, kisspeptin‑10 given after insulin did not help; blood sugar fell lower than with insulin alone.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseBlood glucose at 180 min after insulin
    Study

    rhesus monkeyn = 6

    Streptozotocin-induced diabetic and healthy male monkeys given insulin
    Comparator
    Insulin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    KP-10 post-insulin treatment, however, remained ineffective and led, instead, to significantly decreased glucose concentrations by 180 min in both diabetic and healthy animals when compared to animals treated with insulin alone.
    2 context sentences
    Summary · context
    Thirty-six adult male rhesus monkeys were used, six in each group.
    Summary · context
    Diabetes was induced with streptozotocin (45 mg/kg b.w.; single dose i.v.).

Studies that did not test the peptide alone1

In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Kisspeptin-10.

  1. 04AnimalNot a test of Kisspeptin-10 aloneAnimal study (in vivo)Efficacy outcome

    In diabetic and healthy rhesus monkeys, the kisspeptin antagonist P234 followed by insulin abolished the preventive action of kisspeptin, and blood glucose decreased significantly.

    In plain wordsIn rhesus monkeys, a kisspeptin blocker given before insulin removed the protective effect and blood sugar fell.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseBlood glucose after P234 antagonist plus insulin
    Study

    rhesus monkeyn = 6

    Streptozotocin-induced diabetic and healthy male monkeys given insulin
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Treatment with P234 antagonist followed by insulin administration abolished the preventive action of kisspeptin, whereby blood glucose decreased significantly (p < 0.001) in both diabetic and healthy animals.
    2 context sentences
    Summary · context
    Thirty-six adult male rhesus monkeys were used, six in each group.
    Summary · context
    Diabetes was induced with streptozotocin (45 mg/kg b.w.; single dose i.v.).

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.